|Novel Combination Therapies in HR+/HER2- Metastatic Breast Cancer: New Standards of Care?
||CME Credits: 1
|Historically, the cornerstone of the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer has been endocrine therapy. Unfortunately, the development of endocrine resistance can limit the efficacy of this approach.
|Faculty: Karen Lisa Smith, MD, MPH, and Maria Raquel Nunes, MD